Myriad Genetics has agreed to sell its prenatal health business to LabCorp for $210 million.

Oct 20, 2026, 8:38 AM ETDealRead the original at SEC EDGAR

Neutral

Myriad agreed to sell its prenatal testing business for $210 million in cash plus inventory value. It would also give up those products, and the filing does not show enough to change the company's outlook.

MYGN · Myriad Genetics, Inc.

AI read · Neutral

The AI's read

The sale would give Myriad cash, but it would also transfer several tests and related obligations to Labcorp. The filing gives no sales or profit figures for that business, so the payment cannot be compared with what Myriad is giving up. The sale also needs approvals and other closing conditions.

Get alerts for MYGN

Follow Myriad Genetics, Inc. (MYGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MYGN

Free on the App Store and Google Play, or on the web.